Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.

@article{Magee2015RiskbenefitCW,
  title={Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.},
  author={Alan G. Magee and Sukeshi Makhecha and Si{\^a}n Bentley},
  journal={Expert opinion on drug safety},
  year={2015},
  volume={14 5},
  pages={633-42}
}
INTRODUCTION Sildenafil (Revatio®) and tadalafil (Adcirca®) are specific inhibitors of the phosphodiesterase-5 enzyme and produce pulmonary vasodilation by inhibiting the breakdown of cyclic guanosine monophosphate (cGMP) in the walls of pulmonary arterioles. AREAS COVERED We focus on the efficacy and safety of sildenafil and tadalafil in the treatment of… CONTINUE READING